the association between ADAMTS13 and all-cause mortality are lacking.
We, therefore, aimed to investigate the association between VWF levels, ADAMTS13 activity, and all-cause mortality. We further examined the association between VWF levels, ADAMTS13 activity, and cause-specific mortality, in particular mortality because of CVD, cancer, and chronic obstructive pulmonary disease (COPD).
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Briefly, this study is part of the Rotterdam study, a prospective population-based cohort study among individuals aged ≥55 years who are all living in Ommoord, a suburb of Rotterdam, The Netherlands. We included all participants who were alive at baseline and of whom blood was sampled (n=6511). 14 Information on mortality was reported through general practitioner files and municipal records and coded according to the International Classification of Diseases, Tenth Revision. VWF antigen (VWF:Ag) levels were determined with an in-house ELISA. Polyclonal rabbit antihuman VWF antibodies were used for catching and tagging (DakoCytomation, Glostrup, Denmark). ADAMTS13 activity was measured in a kinetic assay with the previously described Fluorescence Resonance Energy Transfer Substrate VWF 73. 15 Mean and SD or counts and percentages were used to describe baseline characteristics. Proportional hazards assumption was drawn to determine log-minus-log plots. The association between ADAMTS13 activity, VWF levels, and mortality was assessed using Cox proportional hazard regression analysis.
Results
In total, 6130 individuals were included in this study. The mean age of the included individuals was 69±8.0 years, and 57% was female individuals ( Table 1 ). The median VWF:Ag level was 1.19 IU/mL (interquartile range: 0.92-1.58 IU/mL), and the mean ADAMTS13 activity was 91.8±17.6%. During the median follow-up time of 11.3 years and a total of 90 635 person years, 1868 (30.5%) individuals died, 442 of them (23.7%) because of CVD, 518 (27.7%) because of cancer, and 59 (3.2%) because of COPD.
After adjusting for confounders, the risk of all-cause mortality was significantly higher in individuals in the lowest ADAMTS13 quartile than that in individuals with the highest ADAMTS13 (hazard ratio [HR], 1.46; 95% confidence interval [CI], 1.26-1.69; Table 2 ). The risk of cardiovascular mortality was also increased in individuals with the lowest ADAMTS13 activity (HR, 1.46; 95% CI, 1.09-1.96). The risks of cancer-related mortality and COPD-related mortality were 1.30 and 1.91, albeit not statistically significant (HR, 1.30; 95% CI, 0.99-1.71 and HR, 1.91; 95% CI, 0.69-5.32, respectively).
In individuals in the highest VWF quartile, the risk of allcause mortality was increased compared with individuals in the lowest quartile of VWF (HR, 1.21; 95% CI, 1.06-1.38; Table 3 ). When we analyzed the different mortality causes, the risk estimate of cardiovascular-related mortality (HR, 1.29; 95% CI, 0.98-1.70) was similar to the risk of all-cause mortality. No association was observed between VWF:Ag levels and COPD mortality (HR, 1.07; 95% CI, 0.83-1.37) and cancer mortality (HR, 1.02; 95% CI, 0.80-1.30).
The lowest ADAMTS13 and the highest VWF quartiles were both associated with the lowest event-free survival after adjustment for age and sex ( Figure) .
In individuals with both high VWF:Ag levels and low ADAMTS13 activity (n=448), the risk of all-cause mortality was strongly increased compared with individuals with both low VWF:Ag levels and high ADAMTS13 activity ( Table 4 ). Of these 448 individuals, 247 individuals (55.1%) died during follow-up compared with 22.6% in the group individuals with low VWF:Ag levels and high ADAMTS13 activity. Individuals with both high VWF levels and low ADAMTS13 activity had a 58% increased risk of all-cause mortality (HR, 1.58; 95% CI, 1.36-1.84). Also, the risk of cardiovascular mortality was increased most strongly in individuals with both low ADAMTS13 activity and high VWF levels (HR, 1.73; 95% CI, 1.28-2.35). The risks of cancer-related mortality and COPD-related mortality were both increased with the combination of low ADAMTS13 activity and high VWF levels, 
Discussion
In this large prospective cohort study with a median followup time of 11.3 years and a total of 90 635 person years, ADAMTS13 activity and VWF:Ag levels were associated with an increased risk of mortality and specifically cardiovascular mortality. These risks were independent of prevalent CVD and established cardiovascular risk factors.
We found an association between low ADAMTS13 activity and the risk of all-cause and cardiovascular mortality. Recently, we have shown that low ADAMTS13 activity is associated with an increased risk of ischemic stroke and coronary heart disease, 8, 16, 17 but no studies on the association with mortality have been performed to date. We found that individuals with low ADAMTS13 activity (<80.7%) had a 1.46-fold higher risk of mortality than individuals with high ADAMTS13 activity. In individuals with the lowest ADAMTS13 activity, the risk estimates of all-cause and cardiovascular mortality (HR, 1.46 for both) were similar, suggesting that the risk of all-cause mortality might be driven by an increased risk of CVD.
We found an increased risk of all-cause mortality in individuals with the highest VWF:Ag levels. In addition, there was a borderline significant association between cardiovascular mortality and high VWF:Ag levels, although the risk estimate was higher compared with all-cause mortality. This might be explained by the smaller number of cases in this subgroup. These results indicate that ADAMTS13 activity may play a more prominent role in CVD in our elderly study population. Previous studies using the Rotterdam study have already found a higher cardiovascular risk in individuals with a low ADAMTS13 activity than in those with a high VWF:Ag level. 5, 8, 18 The association between VWF levels and cardiovascular mortality has been reported before. [9] [10] [11] [12] [13] However, these studies only investigated cardiac-specific or cardiovascular mortality, and no studies are performed yet on the association with all-cause mortality and cause-specific mortality.
Compared with individuals with both low VWF levels and high ADAMTS13 activity, we found that individuals with a high VWF:Ag level and low ADAMTS13 activity had an increased risk of all-cause and cardiovascular mortality of ≤1.73-fold, although this was only a small subgroup of individuals (24.1% and 7.3%, respectively). This finding suggests that VWF levels and ADAMTS13 activity could be independent risk factors and might have an additive effect, which was also shown before. 8 The mechanism by which low ADAMTS13 activity is associated with cardiovascular mortality was not addressed in this epidemiological study. It is well known that reduced levels of ADAMTS13 lead to less cleavage of ultralarge, highly active, VWF multimers. 3 Especially in combination with high VWF:Ag levels, this may lead to a prothrombotic phenotype. Especially at sites of vascular damage, such as in atherosclerotic lesions, VWF is locally secreted from the endothelium as large multimers, and in combination with low ADAMTS13 levels, this may lead to thrombus formation and thrombus growth and arterial Figure. Kaplan-Meier curves for von Willebrand factor antigen (VWF:Ag) levels and ADAMTS13 activity. Kaplan-Meier curve for the cumulative survival for all-cause mortality per quartile of ADAMTS13 activity (A) and VWF:Ag levels (B) adjusted for age and sex. Kaplan-Meier curve for the cumulative survival for cardiovascular mortality per quartile of ADAMTS13 activity (C) and for VWF:Ag levels (D) adjusted for age and sex. Cut points for ADAMTS13 quartiles were: ≤70.99%, 71.00% to 90.80%, 90.81% to 111.51%, and ≥111.52%. Cut points for VWF quartiles were: ≤0.56, 0.57 to 1.09, 1.10 to 1.82, and 1.83 IU/L. December 2016 thrombotic complications, which will eventually lead to an increase of cardiovascular mortality. It is evident that additional mechanistic studies are needed to strengthen this hypothesis.
The risks of cancer-and COPD-related mortality were not increased in individuals with either high VWF:Ag levels or low ADAMTS13 activity, although we observed a borderline significant increased risk of cancer-related mortality in individuals with the lowest ADAMTS13 activity. Cancer and COPD are both common causes of mortality. Previous studies have shown a relation between high VWF levels and cancer, [19] [20] [21] [22] COPD, 23, 24 or inflammation, 25 and also, an association between ADAMTS13 and inflammation was shown before. [26] [27] [28] This would suggest that there may be an association between high VWF levels, low ADAMTS13 activity, and cancer-or COPD-related mortality. However, the lack of this association in our study suggests that ADAMTS13 activity and VWF levels are influenced by other mechanisms such as inflammation in patients with COPD or cancer, and their effect might be explained by alternative factors.
To date, this study investigated the association between VWF:Ag levels, ADAMTS13 activity, and the risk of all-cause and cardiovascular mortality in a population that is representative for the Dutch population. We had a long follow-up time of 11.3 years in which many individuals died (30.5%). However, only 59 participants died because of COPD-related mortality, which was too small to have sufficient power to evaluate the association. Moreover, VWF levels and ADAMTS13 activity could have been influenced by an already existing disease at the moment of blood sampling. Therefore, we excluded all individuals who died within the first 3 years after blood sampling to reduce this influence. Our study was performed in a population of predominantly whites aged ≥55 years who live in a middle-income district of Rotterdam. This limits the generalizability of our results, especially for younger individuals.
In conclusion, we observed in this large prospective cohort study with a long follow-up time an association between high VWF levels, low ADAMTS13 activity, and all-cause or cardiovascular mortality. This risk increased ≤1.73-fold in individuals with both high VWF and low ADAMTS13 levels. Model 1 adjusted for age and sex. Model 2 additionally adjusted for antithrombotic agents, antihypertensives, diabetes mellitus, lipid-reducing agents, BMI, current smoking, total cholesterol, HDL cholesterol, systolic blood pressure, and diastolic blood pressure.
Model 3 additionally adjusted for prevalent cardiovascular disease. ADAMTS13 indicates a disintegrin and metalloprotease with thromboSpondin motif repeats 13; BMI, body mass index; CI, confidence interval; HDL, high-density lipoprotein; HR, hazard ratio; VWF, von Willebrand factor; and VWF:Ag, von Willebrand factor antigen.
